Voiding Dysfunction

Bladder Wall Thickness is Associated with Responsiveness of Storage Symptoms to Alpha-Blockers in Men with Lower Urinary Tract Symptoms

Jung Soo Park, Ho Won Lee, Seung Wook Lee, Hong Sang Moon, Hae Young Park, Yong Tae Kim
Department of Urology, Hanyang University College of Medicine, Seoul, Korea

Purpose: Bladder wall thickness (BWT) is reported to be related to detrusor overactivity and bladder outlet obstruction. We investigated the relationship between BWT and the responsiveness of storage symptoms to alpha-blockers in men with lower urinary tract symptoms (LUTS).

Materials and Methods: A total of 74 patients with LUTS were enrolled. International Prostate Symptom Score, uroflowmetry with post-void residual urine volume, and transrectal ultrasonography (TRUS) were investigated. BWT was measured by performing TRUS at the midsagittal plane view, and the average value of BWT at the anterior, dome, and trigone areas was used. After 4 weeks of alpha-blocker medication, patients were reevaluated and divided into two groups. The responder group consisted of patients who reported improvement in the storage symptom subscore of 2 points or more; the non-responder group consisted of patients who reported improvement of less than 2 points. Clinical parameters including BWT were compared between the two groups.

Results: A total of 52 patients were followed. BWT was positively correlated with intravesical prostate protrusion (IPP) (9.26±4.99, standardized beta=0.393, p=0.002) and storage symptom subscore (0.35±0.43, standardized beta=0.458, p=0.002). Compared with that in the responder group, BWT was thicker in the non-responder group, and improvement in the storage symptom score was correlated with BWT (0.58±0.09 cm vs. 0.65±0.11 cm, p=0.018) and prostate volume (27.08±16.26 ml vs. 36.44±10.1 ml, p=0.018).

Conclusions: BWT was correlated with IPP, the storage symptom subscore, and the responsiveness of storage symptoms to alpha-blockers in LUTS/benign prostatic hyperplasia (BPH) patients. As BWT increased, the responsiveness of storage symptoms to alpha-blocker decreased in LUTS/BPH patients.

Key Words: Adrenergic alpha-antagonists; Lower urinary tract symptoms; Muscarinic antagonists

INTRODUCTION

Bladder outlet obstruction (BOO) is associated with changes in detrusor structure that can account for the resultant voiding dysfunction. Significant detrusor muscle hypertrophy is a well-recognized clinical finding seen in association with several obstructive disorders of the lower urinary tract, such as benign prostatic hyperplasia (BPH) [1]. Features of the myohypertrophy can explain the overall weakness of the obstructed detrusor despite hypertrophy of its cells and involuntary contractions of the obstructed detrusor [2].
Observation of a thickened or trabeculated bladder wall is considered to be of great significance in the diagnosis of obstruction. Many studies have been conducted of the clinical usefulness of measurement of bladder wall thickness (BWT). Currently, the clinical usefulness of BWT remains controversial, but interest is increasing in its clinical significance [3-5].

In terms of the guidelines established by the American Urological Association or the European Association of Urology, antimuscarinic agents can be used when lower urinary tract symptoms (LUTS) are predominantly irritative with caution or post-voided residual (PVR) urine volume [6]. The results of studies reported by Abrams et al. [7], Lee et al. [8], and Kaplan et al. [9] support antimuscarinic therapy for treating men with BPH and overactive bladder (OAB) symptoms. They reported that additive antimuscarinic agents to alpha-blocker and/or a 5-alpha-reductase inhibitor for patients with BPH/BOO and OAB are well tolerated and more efficacious in improving storage symptoms. However, debate remains concerning the criteria for use of antimuscarinic agents in treating patients with LUTS and BPH.

Given the above background, we supposed that BWT would be correlated with irritative lower urinary symptoms. We also supposed that alpha-blocker monotherapy would not improve irritative LUTS. To demonstrate these assumptions, we investigated the relationship between BWT and symptoms in patients with LUTS/BPH. We also investigated the relationship between BWT and the responsiveness of the storage symptoms to alpha-blockers in men with LUTS.

MATERIALS AND METHODS

1. Study protocol

From January 2011 to February 2011, 74 men with LUTS who were older than 40 years were reviewed retrospectively. Patients with an International Prostate Symptom Score (IPSS) over 8 and prostate volume over 20 ml were included. Included patients had no previous medical consultation or treatment for LUTS. Exclusion criteria were PVR over 150 ml, diagnosis of prostate cancer, bladder tumor, bladder stone, urethral stricture, urinary tract infection, previous prostate surgery, neurogenic bladder, hypersensitivity to alpha-blockers, and disorders of the liver or kidney. Patients were evaluated by IPSS, uroflowmetry (Medtronic Inc., Minneapolis, MN, USA), and PVR by transabdominal ultrasonography (US) and transrectal US (TRUS).

After the initial evaluations, an alpha-blocker was prescribed to all patients for 4 weeks. Alpha-blockers were tamsulosin 0.2 mg or doxazosin 4 mg or alfuzosin 10 mg. After 4 weeks of medication, the IPSS was reevaluated and the patients were divided into two groups. The responder group included patients who reported improvement of the IPSS storage symptom subscore of 2 points or more; the nonresponder group included patients who improved less than 2 points. We compared the relationship of the clinical parameters and BWT between the two groups (Fig. 1).

2. Transrectal ultrasonography (TRUS) measurement

TRUS was performed by one urologist to minimize the sampling bias. TRUS was done with a 6.5 MHz probe (SA-8000, Medison, Seoul, Korea) when bladder volume was approximately 100 ml. BWT was measured by performing TRUS with the 6.5 MHz linear probe in the midsagittal plane view at maximum magnification (Fig. 2). BWT was defined as the length between the outer and inner muscle surface, which was identified by hyperechogenic lines corresponding to subserosal tissue and to bladder mucosa plus submucosal tissue, respectively. It was measured at three different anatomical points: the anterior, the dome, and the...
trigone of the bladder, and the average value of measured BWT was used. In performing TRUS, the vertical distance from the tip of the prostate protrusion into the bladder to the bladder circumference at the prostate base in the mid-sagittal plane, which is termed intravesical prostate protrusion (IPP), was also measured.

3. Statistical analysis
Statistical analysis was referred to a statistics specialist, and SAS ver. 9.2 (SAS Inc., Cary, NC, USA) was used. The relation of each variable with BWT was examined by multiple linear regression analysis. Comparison between the two groups, before and after alpha-blocker administration, was analyzed by using independent t-tests and paired t-tests. Continuous data were reported as the mean±standard deviation. A 5% level of significance was used for all statistical testing.

RESULTS
At the time the study started, 74 LUTS/BPH patients were enrolled, but 52 patients were followed. The patients' mean age was 61.2±10.8 years, and mean prostate volume was 37.2±14.7 ml, and mean prostate-specific antigen (PSA) was 2.0±2.8 ng/ml. BWT was positively correlated with IPP (9.26±4.99, standardized beta=0.393, p=0.002) and the storage symptom subscore (0.35±0.43, standardized beta=0.458, p=0.002) (Table 1). BWT had a slightly negative correlation with the maximal urine flow rate (12.73±8.81, standardized beta=-0.231, p=0.032).

After 4 weeks of alpha-blocker medication, improvement of the IPSS storage symptom subscore of 2 points or more was observed in 29 patients (responder group); the other 23 patients (non-responder group) reported improvement of less than 2 points. There were no significant differences in age, PSA, IPP, maximal urine flow rate, or PVR between the two groups (Table 2). Between the two groups, there was a significant difference in prostate volume and BWT.

| Variable                  | Beta (β) | Standardized beta | p-value |
|---------------------------|----------|-------------------|---------|
| Age (yr)                  | 0.001    | 0.037             | 0.734   |
| Voiding symptom score     | -0.008   | -0.202            | 0.162   |
| Storage symptom score     | 0.017    | 0.458             | 0.002   |
| QoL                       | -0.018   | -0.115            | 0.355   |
| PSA (ng/ml)               | 0.001    | 0.014             | 0.888   |
| Prostate volume (ml)      | -0.003   | -0.274            | 0.401   |
| T-zone volume (ml)        | 0.005    | 0.353             | 0.266   |
| IPP (cm)                  | 0.163    | 0.393             | 0.002   |
| Qmax (ml/s)               | -0.005   | -0.231            | 0.032   |
| PVR (ml)                  | 0.000    | 0.031             | 0.907   |

QoL, quality of life; PSA, prostate-specific antigen; IPP, intravesical prostate protrusion; Qmax, maximal urine flow rate; PVR, post-voided residual urine volume.

The non-responder group had a larger prostate volume (27.08±16.26 ml vs. 36.44±10.1 ml, p=0.018) and thicker BWT than did the responder group (0.58±0.09 cm vs. 0.65±0.11 cm, p=0.018). However, the statistical analysis revealed that prostate volume had no significant influence in either group (Table 3). There was a significant improvement in total IPSS and the voiding symptom subscore in both groups after 4 weeks of alpha-blocker medication (Table 3, 4).

| Variable                  | Responding group (n=29) | Nonresponding group (n=23) | p-value |
|---------------------------|-------------------------|-----------------------------|---------|
| PSA (ng/ml)               | 2.33±3.12               | 2.07±2.32                   | 0.737   |
| Prostate volume (ml)      | 27.08±16.26             | 36.44±10.14                 | 0.018   |
| T-zone volume (ml)        | 19.10±9.23              | 20.73±7.69                  | 0.494   |
| IPP (cm)                  | 0.23±0.28               | 0.42±0.42                   | 0.051   |
| BWT (cm)                  | 0.58±0.09               | 0.65±0.11                   | 0.018   |
| Qmax (ml/s)               | 14.14±9.05              | 11.62±8.65                  | 0.312   |
| PVR (ml)                  | 45.29±43.82             | 50.79±53.65                 | 0.686   |

PSA, prostate-specific antigen; IPP, intravesical prostate protrusion; BWT, bladder wall thickness; Qmax, maximal urine flow rate; PVR, post-voided residual urine volume.

3. Statistical analysis
Statistical analysis was referred to a statistics specialist, and SAS ver. 9.2 (SAS Inc., Cary, NC, USA) was used. The relation of each variable with BWT was examined by multiple linear regression analysis. Comparison between the two groups, before and after alpha-blocker administration, was analyzed by using independent t-tests and paired t-tests. Continuous data were reported as the mean±standard deviation. A 5% level of significance was used for all statistical testing.

RESULTS
At the time the study started, 74 LUTS/BPH patients were enrolled, but 52 patients were followed. The patients' mean age was 61.2±10.8 years, and mean prostate volume was 37.2±14.7 ml, and mean prostate-specific antigen (PSA) was 2.0±2.8 ng/ml. BWT was positively correlated with IPP (9.26±4.99, standardized beta=0.393, p=0.002) and the storage symptom subscore (0.35±0.43, standardized beta=0.458, p=0.002) (Table 1). BWT had a slightly negative correlation with the maximal urine flow rate (12.73±8.81, standardized beta=-0.231, p=0.032).

After 4 weeks of alpha-blocker medication, improvement of the IPSS storage symptom subscore of 2 points or more was observed in 29 patients (responder group); the other 23 patients (non-responder group) reported improvement of less than 2 points. There were no significant differences in age, PSA, IPP, maximal urine flow rate, or PVR between the two groups (Table 2). Between the two groups, there was a significant difference in prostate volume and BWT.

| Variable                  | Beta (β) | Standardized beta | Odds ratio | p-value |
|---------------------------|----------|-------------------|------------|---------|
| Prostate volume (ml)      | 0.195    | 1.037             | >999.999   | 0.002   |
| BWT (cm)                  | 1.207    |                   | >999.999   |         |

The non-responder group had a larger prostate volume (27.08±16.26 ml vs. 36.44±10.1 ml, p=0.018) and thicker BWT than did the responder group (0.58±0.09 cm vs. 0.65±0.11 cm, p=0.018). However, the statistical analysis revealed that prostate volume had no significant influence in either group (Table 3). There was a significant improvement in total IPSS and the voiding symptom subscore in both groups after 4 weeks of alpha-blocker medication (Tables 3, 4).

DISCUSSION
Urodynamic study is the gold standard clinical test for assessing lower urinary tract function. However, it is time consuming and invasive with associated morbidity [10]. Interest has therefore arisen in the development of non-invasive methods for assessing lower urinary tract function. The diagnostic potential of measurements of BWT, detrusor wall thickness, and US-estimated bladder function. The diagnostic potential of measurements of BWT, detrusor wall thickness, and US-estimated bladder function. The diagnostic potential of measurements of BWT, detrusor wall thickness, and US-estimated bladder function. The diagnostic potential of measurements of BWT, detrusor wall thickness, and US-estimated bladder function.
ly separated muscle cells with reduction of intermediate cell junctions and collagen deposition in the markedly wid-
ed spaces between individual muscle cells and abundant profiles characteristic of enlarged, hypertrophic muscle cells. BOO is associated with changes in detrusor structure that can account for the resultant voiding dysfunction. Features of the myohypertrophy pattern can explain the overall weakness of the obstructed detrusor despite hyper-
trophy of its cells. Protrusion junctions and abutments probably mediate electrical coupling of muscle cells, thus leading to involuntary contractions in the overactive ob-
structed detrusor [2].

Frequent detrusor contractions during the storage phase while the bladder outlet is obstructed are presumed to increase the work load on the muscle with consequent hypertrophy [19,20]. In the largest such study, Hakenberg et al. [5] reported mean transabdominal US measurements of BWT in 172 healthy men and 166 healthy women of 3.33 and 3.04 mm, respectively. Khullar et al. [21] found signifi-
cant differences in median BWT between female patients with OAB due to detrusor overactivity (DO) and those with-
out DO. A cut-off BWT of 5 mm had 84% sensitivity and 89% specificity for DO. Serati et al. [22] reported significantly thick BWT in patients with urodynamic “pure DO” with 13.33% sensitivity and 97.67% specificity for DO.

The bladder wall consists of bladder adventitia, which gives a hyperechoic (bright) appearance on US, and then the bladder muscle layer, which gives a hypoechoic (dark) appearance on US. The innermost layer is the bladder mu-
cosa, which gives a hyperechoic (bright) appearance on US. BWT is measured by including the inner and outer hypo-
echoic lines in the measurement [23,24].

Given the above background, we assumed that BWT could be a useful, noninvasive parameter for evaluation of LUTS/BPH patients.

As Khullar et al. [21] founded in female OAB patients, BWT was positively correlated to IPSS storage subscore in male LUTS/BPH patients, as shown in Table 1. BWT was also positively correlated with IPP, which is related to the progression of BOO due to BPH [25]. BWT was correlated with the storage symptom score in LUTS/BPH patients.

Because medical treatment is the first option for LUTS/BPH patients [26], we prescribed selective al-
pha-blockers to the patients for 4 weeks and divided the pa-
ients into two groups according to the degree of improve-
ment in the IPSS storage symptom subscore. We expected that the IPSS storage subscore would not improve in LUTS/BPH patients with larger BWT after alpha-blocker monotherapy. We supposed that the bladder dysfunction induced by bladder wall hypertrophy, such as DO, would not completely improve after the BOO was relieved with alpha-blocker treatment.

The result was, as shown in Table 2, like we expected. Patients in the non-responder group had a larger BWT and larger prostate volume. But as shown in Table 3, larger prostate volume had little influence in the non-responder group. Only BWT had a significant influence in the non-
responder group. As shown in Table 4, the IPSS voiding subscore was significantly improved in both groups. The IPSS storage subscore had little influence in the responder group and endpoint values.

### TABLE 4. Comparison of IPSS total score and subscores in responders and non-responders with alpha blocker

|                      | Total          | Responder group (n=29) | Nonresponder group (n=23) | p-valuea |
|----------------------|----------------|------------------------|---------------------------|---------|
| **IPSS total score** | 17.73±8.25     | 20.45±7.74             | 14.30±7.71                | 0.006   |
| Endpoint             | 10.56±6.52     | 9.69±5.24              | 11.65±7.83                | 0.286   |
| p-valueb             | <0.001         | 0.001                  |                           |         |
| Difference           | -7.17±6.38     | -10.76±5.87            | -2.65±3.49                | <0.001  |
| **IPSS storage subscore** | 9.31±5.06    | 11.34±4.43             | 6.74±4.70                 | <0.001  |
| Endpoint             | 6.65±4.20      | 6.38±3.72              | 7.00±4.81                 | 0.602   |
| p-valueb             | <0.001         | 0.248                  |                           |         |
| Difference           | -2.65±3.37     | -4.97±2.71             | 0.26±1.05                 | <0.001  |
| **IPSS voiding subscore** | 8.42±4.11     | 9.10±4.13              | 7.57±3.99                 | 0.182   |
| Endpoint             | 3.90±3.11      | 3.31±2.17              | 4.65±3.93                 | 0.124   |
| p-valueb             | <0.001         | <0.001                 |                           |         |
| Difference           | -4.52±3.80     | -5.79±3.87             | -2.91±3.09                | 0.005   |

IPSS, International Prostate Symptom Score.

a: Independent t-test was performed between responder group and non-responder group, b: Paired t-test was performed between baseline and endpoint values.
enrolled and analyzed patients was small. Because of this, the IPSS before medication was significantly different in the two groups. Moreover, we did not perform urodynamics study. The duration of alpha-blocker therapy was not long enough to reverse the detrusor change that is induced by BOO. Also, there was no placebo group for comparison. In order to understand the effect of BWT in LUTS/BPH patients, randomized, large-scale, and controlled studies of longer duration are necessary.

CONCLUSIONS

BWT was related to IPP and the storage symptom score in LUTS/BPH patients. With BWT increase, the responsiveness of alpha-blockers to irritative symptom was decreased in LUTS/BPH patients. BWT may be a useful parameter for predicting responsiveness of irritative symptoms to alpha-blocker therapy in LUTS/BPH patients.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

REFERENCES

1. Manieri C, Carter SS, Romano G, Trucchi A, Valenti M, Tubaro A. The diagnosis of bladder outlet obstruction in men by ultrasonic measurement of bladder wall thickness. J Urol 1998;159:761-5.
2. Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. IV. Bladder outlet obstruction. J Urol 1993;150(5 Pt 2):1681-95.
3. Farag FF, Heesakkers JP. Non-invasive techniques in the diagnosis of bladder storage disorders. Neurourol Urodyn 2011;30:1422-8.
4. Bright E, Oelke M, Tubaro A, Abrams P. Ultrasound estimated bladder weight and measurement of bladder wall thickness—useful noninvasive methods for assessing the lower urinary tract? J Urol 2010;184:1847-54.
5. Hakenberg OW, Linne C, Manseck A, Wirth MP. Bladder wall thickness in normal adults and men with mild lower urinary tract symptoms and benign prostatic enlargement. Neurourol Urodyn 2000;19:585-93.
6. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011;185:1793-803.
7. Abrams P, Kaplan S, De Koning HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006;175(3 Pt 1):999-1004.
8. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004;94:817-20.
9. Kaplan SA, Walmsey K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005;174:2273-5.
10. Klingler HC, Madersbacher S, Djavan B, Schatzl G, Marberger M, Schmidbauer CP. Morbidity of the lower urinary tract with transurethral multichannel pressure-flow studies. J Urol 1998;159:191-4.
11. Oelke M, Hofner K, Wiese B, Grunewald V, Jonas U. Increase in detrusor wall thickness indicates bladder outlet obstruction (BOO) in men. World J Urol 2002;19:443-52.
12. Kessler TM, Gerber R, Burkhard FC, Studer UE, Danuser H. Ultrasound assessment of detrusor thickness in men—can it predict bladder outlet obstruction and replace pressure flow study? J Urol 2006;175:2170-3.
13. Oelke M, Hofner K, Jonas U, de la Rosette JJ, Ubbink DT, Wijkstra H. Diagnostic accuracy of noninvasive tests to evaluate bladder outlet obstruction in men: detrusor wall thickness, uroflowmetry, postvoid residual urine, and prostate volume. Eur Urol 2007;52:827-34.
14. Kojima M, Inui E, Ochiai A, Naya Y, Ukimura O, Watanabe H. Noninvasive quantitative estimation of infravesical obstruction using ultrasonic measurement of bladder weight. J Urol 1997;157:476-8.
15. Levin RM, Hauggaard N, O’Connor L, Buttyan R, Das A, Dixon JS, et al. Obstructive response of human bladder to BPH vs. rabbit bladder response to partial outlet obstruction: a direct comparison. Neurourol Urodyn 2000;19:609-29.
16. Mattiasson A, Uvelius B. Changes in contractile properties in hypertrophic rat urinary bladder. J Urol 1982;128:1340-2.
17. Kim SO, Song SH, Ahn K, Kwon D, Park K, Ryu SB. Changes in aquaporin 1 expression in rat urinary bladder after partial bladder outlet obstruction: preliminary report. Korean J Urol 2010;51:281-6.
18. Ghoniem GM, Regnier CH, Biancapi P, Johnson L, Susset JG. Effect of vesical outlet obstruction on detrusor contractility and passive properties in rabbits. J Urol 1986;135:1284-9.
19. Khullar V, Salvatore S, Cardozo I, Bourne TH, Abbott D, Kelleher C. A novel technique for measuring bladder wall thickness in women using transvaginal ultrasound. Ultrasound Obstet Gynecol 1994;4:220-3.
20. Lekskulchai O, Dietz HP. Detrusor wall thickness as a test for detrusor overactivity in women. Ultrasound Obstet Gynecol 2008;32:535-9.
21. Khullar V, Cardozo LD, Salvatore S, Hill S. Ultrasound: a noninvasive screening test for detrusor instability. Br J Obstet Gynaecol 1996;103:904-8.
22. Serati M, Salvatore S, Cattoni E, Soligo M, Cromi A, Ghezzi F. Ultrasonic measurement of bladder thickness in different forms of detrusor overactivity. Int Urogynecol J 2010;21:1405-11.
23. Jequier S, Rousseau O. Sonographic measurements of the normal bladder wall in children. AJR Am J Roentgenol 1987;149:563-6.
24. Kojima M, Inui E, Ochiai A, Naya Y, Ukimura O, Watanabe H. Ultrasonic estimation of bladder weight as a measure of bladder hypertrophy in men with infravesical obstruction: a preliminary report. Urology 1996;47:942-7.
25. Lee LS, Sim HG, Lim KB, Wang D, Foo KT. Intravesical prostatic protrusion predicts clinical progression of benign prostatic enlargement in patients receiving medical treatment. Int J Urol 2010;17:69-74.
26. Choi SY, Kim TH, Myung SC, Moon YT, Kim KD, Kim YS, et al. Impact of changing trends in medical therapy on surgery for benign prostatic hyperplasia over two decades. Korean J Urol 2012;53:23-8.
27. Greco KA, McVary KT. The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res 2008;20 Suppl 3:S31-43.